JP2012521217A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012521217A5 JP2012521217A5 JP2012502150A JP2012502150A JP2012521217A5 JP 2012521217 A5 JP2012521217 A5 JP 2012521217A5 JP 2012502150 A JP2012502150 A JP 2012502150A JP 2012502150 A JP2012502150 A JP 2012502150A JP 2012521217 A5 JP2012521217 A5 JP 2012521217A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- composition
- antigen
- binding fragment
- linker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16234809P | 2009-03-23 | 2009-03-23 | |
| US61/162,348 | 2009-03-23 | ||
| PCT/US2010/028200 WO2010111198A1 (en) | 2009-03-23 | 2010-03-23 | Compounds compositions and methods of treating cancer and fibrotic diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015159597A Division JP2016034945A (ja) | 2009-03-23 | 2015-08-12 | 癌および線維性疾患を治療する化合物、組成物、および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012521217A JP2012521217A (ja) | 2012-09-13 |
| JP2012521217A5 true JP2012521217A5 (https=) | 2013-05-09 |
| JP5830460B2 JP5830460B2 (ja) | 2015-12-09 |
Family
ID=42288813
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012502150A Expired - Fee Related JP5830460B2 (ja) | 2009-03-23 | 2010-03-23 | 癌および線維性疾患を治療する化合物、組成物、および方法 |
| JP2015159597A Pending JP2016034945A (ja) | 2009-03-23 | 2015-08-12 | 癌および線維性疾患を治療する化合物、組成物、および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015159597A Pending JP2016034945A (ja) | 2009-03-23 | 2015-08-12 | 癌および線維性疾患を治療する化合物、組成物、および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US8444983B2 (https=) |
| EP (1) | EP2411413B1 (https=) |
| JP (2) | JP5830460B2 (https=) |
| CN (2) | CN102378766A (https=) |
| CA (1) | CA2753388C (https=) |
| IL (2) | IL215061A0 (https=) |
| SG (1) | SG174367A1 (https=) |
| WO (1) | WO2010111198A1 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2411413B1 (en) | 2009-03-23 | 2016-05-11 | Quark Pharmaceuticals, Inc. | Compounds compositions and methods of treating cancer and fibrotic diseases |
| JP2015509085A (ja) * | 2012-01-01 | 2015-03-26 | キュービーアイ エンタープライゼズ リミテッドＱｂｉ Ｅｎｔｅｒｐｒｉｓｅｓ Ｌｔｄ． | 治療剤および診断剤の選択的送達のためのｅｎｄｏ１８０を標的とする粒子 |
| EP3003350B1 (en) * | 2013-05-27 | 2018-02-21 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Targeted modulation of macrophages |
| US9572832B2 (en) * | 2013-08-29 | 2017-02-21 | Holy Stone Healthcare Co., Ltd. | Compound of glycosaminoglycan and its fabrication method as well as application |
| AR099812A1 (es) | 2014-03-21 | 2016-08-17 | Abbvie Inc | Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr |
| WO2015179239A1 (en) * | 2014-05-17 | 2015-11-26 | University Of Rochester | Compositions and methods to inhibit estrogen receptor beta for the treatment of renal cell carcinoma |
| WO2016039321A1 (ja) | 2014-09-08 | 2016-03-17 | 国立研究開発法人国立がん研究センター | がん細胞特異的な抗体、抗がん剤、及びがんの検査方法 |
| FI3895736T3 (fi) * | 2016-02-05 | 2023-06-26 | Rigshospitalet | Uparap:hen kohdistuvia vasta-aine-lääkekonjugaatteja |
| JP2019524651A (ja) | 2016-06-08 | 2019-09-05 | アッヴィ・インコーポレイテッド | 抗ｃｄ９８抗体及び抗体薬物コンジュゲート |
| WO2017214322A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
| MX2018015285A (es) | 2016-06-08 | 2019-09-18 | Abbvie Inc | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco. |
| AU2017279550A1 (en) | 2016-06-08 | 2019-01-03 | Abbvie Inc. | Anti-B7-H3 antibodies and antibody drug conjugates |
| US11584932B2 (en) | 2016-11-01 | 2023-02-21 | The Research Foundation For The State University Of New York | 5-halouracil-modified microRNAs and their use in the treatment of cancer |
| CA3043768A1 (en) | 2016-11-29 | 2018-06-07 | PureTech Health LLC | Exosomes for delivery of therapeutic agents |
| EP3554544A4 (en) | 2016-12-16 | 2020-07-29 | Bluefin Biomedicine, Inc. | ANTI-PROTEIN 1 ANTIBODY CONTAINING AN ANTI-CUB DOMAIN (CDCP1), ANTIBODY-DRUG CONJUGATES AND THEIR METHODS OF USE |
| EP3612567B1 (en) | 2017-04-19 | 2024-09-11 | Bluefin Biomedicine, Inc. | Anti-vtcn1 antibodies and antibody drug conjugates |
| CA3066918A1 (en) | 2017-06-12 | 2018-12-20 | Bluefin Biomedicine, Inc. | Anti-il1rap antibodies and antibody drug conjugates |
| JP7232453B2 (ja) * | 2017-09-15 | 2023-03-03 | 学校法人杏林学園 | 糖尿病網膜症、白内障及び／又は腎症モデル実験動物 |
| KR20220124170A (ko) * | 2019-12-05 | 2022-09-13 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 간 섬유증 및 섬유증 관련 기타 질환에 대한 엑소좀 기반 치료요법 |
| WO2021262919A2 (en) | 2020-06-26 | 2021-12-30 | The Research Foundation For The State University Of New York | 5-halouracil-modified micrornas and their use in the treatment of cancer |
| AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
| KR20240024816A (ko) | 2021-06-29 | 2024-02-26 | 릭스하스피탈렛 | 우로키나제 유형 플라스미노겐 활성제 수용체 관련 단백질(uparap)을 표적으로 하는 인간화 항체를 포함하는 항체-약물 접합체 |
| AU2023417911A1 (en) | 2022-12-28 | 2025-05-29 | Adcendo Aps | Antibody-drug conjugates targeting uparap comprising exatecan derivatives |
| WO2025027529A1 (en) | 2023-07-31 | 2025-02-06 | Advesya | Anti-il-1rap antibody drug conjugates and methods of use thereof |
| TW202530255A (zh) | 2023-12-15 | 2025-08-01 | 法商亞維西亞有限公司 | 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物 |
| WO2025141153A1 (en) * | 2023-12-29 | 2025-07-03 | Oncomatryx Biopharma, S.L. | Endo180 targeted antibody-drug conjugates |
| EP4578463A1 (en) * | 2023-12-29 | 2025-07-02 | Oncomatryx Biopharma, S.L. | Endo-180 targeted antibody-drug conjugates |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL81370A (en) * | 1986-02-07 | 1991-06-30 | Genetic Systems Corp | Pharmaceutical and diagnostic compositions comprising a plurality of human monoclonal antibodies for the treatment of bacterial diseases,methods for the preparation of the compositions and antibodies and kits containing said compositions |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US6153737A (en) | 1990-01-11 | 2000-11-28 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
| US6235886B1 (en) | 1993-09-03 | 2001-05-22 | Isis Pharmaceuticals, Inc. | Methods of synthesis and use |
| US5574142A (en) | 1992-12-15 | 1996-11-12 | Microprobe Corporation | Peptide linkers for improved oligonucleotide delivery |
| ES2162863T3 (es) | 1993-04-29 | 2002-01-16 | Unilever Nv | Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae. |
| US5773268A (en) * | 1994-11-09 | 1998-06-30 | Cedars-Sinai Medical Center | Chromosome 21 gene marker, compositions and methods using same |
| US6117977A (en) | 1996-04-24 | 2000-09-12 | Genentech, Inc. | Type C lectins |
| ZA973051B (en) | 1996-04-24 | 1998-10-12 | Genentech Inc | Type c lectins |
| US20050042647A1 (en) | 1996-06-06 | 2005-02-24 | Baker Brenda F. | Phosphorous-linked oligomeric compounds and their use in gene modulation |
| US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| US6251666B1 (en) | 1997-03-31 | 2001-06-26 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid catalysts comprising L-nucleotide analogs |
| US6395713B1 (en) | 1997-07-23 | 2002-05-28 | Ribozyme Pharmaceuticals, Inc. | Compositions for the delivery of negatively charged molecules |
| US6077508A (en) | 1998-03-23 | 2000-06-20 | American Diagnostica Inc. | Urokinase plasminogen activator receptor as a target for diagnosis of metastases |
| WO2000058473A2 (en) | 1999-03-31 | 2000-10-05 | Curagen Corporation | Nucleic acids including open reading frames encoding polypeptides; 'orfx' |
| ES2274781T3 (es) | 1999-04-13 | 2007-06-01 | Wilex Ag | Empleo diagnostico y terapeutico de anticuerpos contra el receptor de la urocinasa. |
| US7829064B2 (en) * | 1999-05-10 | 2010-11-09 | Immunomedics, Inc. | Anti-CD74 immunoconjugates and methods |
| HK1047109A1 (zh) | 1999-10-15 | 2003-02-07 | University Of Massachusetts | 作为指定基因干预工具的rna干预轨迹基因 |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| ES2336887T5 (es) | 2000-03-30 | 2019-03-06 | Whitehead Inst Biomedical Res | Mediadores de interferencia por ARN específicos de secuencias de ARN |
| CA2429814C (en) | 2000-12-01 | 2014-02-18 | Thomas Tuschl | Rna interference mediating small rna molecules |
| EP1423095B1 (en) | 2001-08-14 | 2016-09-28 | Tel Aviv University Future Technology Development L.P. | Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy |
| DE10230997A1 (de) | 2001-10-26 | 2003-07-17 | Ribopharma Ag | Medikament zur Erhöhung der Wirksamkeit eines Rezeptor-vermittelt Apoptose in Tumorzellen auslösenden Arzneimittels |
| US20050119202A1 (en) | 2001-10-26 | 2005-06-02 | Roland Kreutzer | Medicament to treat a fibrotic disease |
| US7795422B2 (en) | 2002-02-20 | 2010-09-14 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA) |
| DE60310944T3 (de) | 2002-08-05 | 2017-08-03 | Silence Therapeutics Gmbh | Weitere neue formen von interferierende rns moleküle |
| AU2003261449A1 (en) | 2002-08-07 | 2004-02-25 | Compositions for rna interference and methods of use thereof | |
| AU2003295600A1 (en) | 2002-11-14 | 2004-06-15 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
| WO2004100759A2 (en) * | 2003-05-19 | 2004-11-25 | Quark Biotech, Inc. | Endo 180 receptor for diagnosis and treatment |
| US7842800B2 (en) | 2004-04-02 | 2010-11-30 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory bacterial and bacterial associated oligonucleotides and uses thereof |
| US8808664B2 (en) | 2004-07-13 | 2014-08-19 | Ramot At Tel-Aviv University Ltd. | Lipidated glycoprotein particles and methods of use |
| EP1789447B1 (en) | 2004-08-16 | 2012-04-25 | Immune Disease Institute, Inc. | Method of delivering rna interference and uses thereof |
| EP1827395A2 (en) | 2004-11-02 | 2007-09-05 | Tel-Aviv University Future Technology Development L.P. | Formulations of water insoluble or poorly water soluble drugs in lipidated glycosaminoglycan particles, their manufacturing and their use for diagnostics and therapy |
| WO2008020435A2 (en) | 2006-08-15 | 2008-02-21 | Quark Pharmaceuticals, Inc | Compositions and methods for treatment of mood disorders |
| JP2010507387A (ja) | 2006-10-25 | 2010-03-11 | クアーク・ファーマスーティカルス、インコーポレイテッド | 新規のｓｉＲＮＡおよびその使用方法 |
| US20100292301A1 (en) | 2007-02-28 | 2010-11-18 | Elena Feinstein | Novel sirna structures |
| US20080311040A1 (en) * | 2007-03-06 | 2008-12-18 | Flagship Ventures | METHODS AND COMPOSITIONS FOR IMPROVED THERAPEUTIC EFFECTS WITH siRNA |
| RU2487716C2 (ru) | 2007-10-03 | 2013-07-20 | Кварк Фармасьютикалс, Инк. | Новые структуры малых интерферирующих рнк (sirna) |
| WO2009108554A2 (en) * | 2008-02-27 | 2009-09-03 | Ramot At Tel Aviv University Ltd. | System for delivery of protein in insoluble fibrillar or aggregate form |
| EP2411413B1 (en) | 2009-03-23 | 2016-05-11 | Quark Pharmaceuticals, Inc. | Compounds compositions and methods of treating cancer and fibrotic diseases |
| AU2010324658A1 (en) | 2009-11-26 | 2012-05-03 | Quark Pharmaceuticals, Inc. | siRNA compounds comprising terminal substitutions |
-
2010
- 2010-03-23 EP EP10722812.4A patent/EP2411413B1/en not_active Not-in-force
- 2010-03-23 CN CN201080012287XA patent/CN102378766A/zh active Pending
- 2010-03-23 SG SG2011065935A patent/SG174367A1/en unknown
- 2010-03-23 JP JP2012502150A patent/JP5830460B2/ja not_active Expired - Fee Related
- 2010-03-23 US US13/255,214 patent/US8444983B2/en active Active
- 2010-03-23 CA CA2753388A patent/CA2753388C/en not_active Expired - Fee Related
- 2010-03-23 CN CN201510009172.XA patent/CN104861066B/zh not_active Expired - Fee Related
- 2010-03-23 WO PCT/US2010/028200 patent/WO2010111198A1/en not_active Ceased
-
2011
- 2011-09-08 IL IL215061A patent/IL215061A0/en active IP Right Grant
-
2013
- 2013-05-02 US US13/886,010 patent/US20140072552A1/en not_active Abandoned
-
2014
- 2014-10-06 IL IL235026A patent/IL235026A/en active IP Right Grant
-
2015
- 2015-07-09 US US14/795,429 patent/US9993567B2/en active Active
- 2015-08-12 JP JP2015159597A patent/JP2016034945A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012521217A5 (https=) | ||
| TWI853077B (zh) | 新型抗ｃｄ３９抗體 | |
| WO2020114480A1 (en) | Anti-claudin antibodies and uses thereof | |
| JP2017526339A5 (https=) | ||
| RU2020120539A (ru) | Композиции для ингибирования masp-2-зависимой активации комплемента | |
| JP2012034692A5 (https=) | ||
| JP2017519501A5 (https=) | ||
| JP2017507936A5 (https=) | ||
| RU2012137515A (ru) | Антитела, связывающиеся с лизилоксидазоподобным ферментом-2 (loxl2), и способы их применения | |
| JP2012100675A5 (https=) | ||
| JP2016512425A5 (https=) | ||
| JP2009225799A5 (https=) | ||
| JP2011502137A5 (https=) | ||
| JP2014039548A5 (https=) | ||
| JP2010511388A5 (https=) | ||
| JP2012510461A5 (https=) | ||
| JP2010533498A5 (https=) | ||
| JP2010523541A5 (https=) | ||
| JP2009521206A5 (https=) | ||
| JP2013121353A5 (https=) | ||
| JP2018502060A5 (https=) | ||
| JP2015212304A5 (https=) | ||
| JP2015527319A5 (https=) | ||
| Tushir-Singh | Antibody-siRNA conjugates: drugging the undruggable for anti-leukemic therapy | |
| JP2011509245A5 (https=) |